Oncolytic HSV-1 expressing FLT3L kills melanoma, glioblastoma, and pancreatic cancer cells <i>in vitro</i> and induces immunogenic cell death.

Mol Ther Oncol · 2025 · PMC12433480 · PMID 40955425

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

IFN-α-2a was detected at low levels and showed a trend toward increase upon addition of oHSV1-FLT3L for 624-mel (48 h), U87 (48 h), BXPC3 (24 h and 48 h), and ASPC1 (24 h and 48 h); however, significance could only be shown for U87 (48 h) and BXPC3 (24 h).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Oncolytic HSV-1 expressing FLT3L kills melanoma, glioblastoma, and pancreatic cancer cells &lt;i&gt;in vitro&lt;/i&gt; and induces immunogenic cell death.

The sentences

Oncolytic HSV-1 expressing FLT3L kills melanoma, glioblastoma, and pancreatic cancer cells <i>in vitro</i> and induces immunogenic cell death.